Skip to main content
TransThera Sciences (Nanjing), Inc. logo

TransThera Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 2617 ISIN · CNE100006T02 HKEX Manufacturing
Open in API
Filings indexed 80 across all filing types
Latest filing 2025-06-09 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2617

About TransThera Sciences (Nanjing), Inc.

https://www.transthera.com

TransThera Sciences (Nanjing), Inc. is a clinical-stage, R&D-driven biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapies. Established in 2014, the company employs a clinical demand-oriented approach to address diseases with significant unmet medical needs. TransThera's pipeline is dedicated to generating first-in-class, best-in-class, and highly differentiated treatments, primarily targeting therapeutic areas such as oncology, inflammatory diseases, and cardiovascular conditions.

Recent filings

Filing Released Lang Actions
PHIP (1st submission)
Regulatory Filings Classification · 75% confidence The document is a Post Hearing Information Pack for TransThera Sciences’ proposed Hong Kong listing, containing detailed offering/prospectus content (IPO structure, risk factors, timetable, underwriting details, financial appendices). It is not an annual or quarterly report, earnings release, management discussion, proxy statement, or board change notice. There is no dedicated prospectus category in our taxonomy, so this detailed regulatory filing falls into the fallback Regulatory Filings category (RNS).
2025-06-09 English
PHIP (1st submission)
Audit Report / Information Classification · 95% confidence The document is a PHIP (Post-Hearing Information Pack) for TransThera Sciences (Nanjing), Inc. on the HKEX. A PHIP is a preliminary document published by a company preparing for an Initial Public Offering (IPO) after the listing hearing. Since it is an announcement providing links to the various sections of the IPO prospectus/filing, it falls under the category of a Report Publication Announcement (RPA) as it serves to notify the public that these documents are now available for review. FY 2024
2025-06-09 English
OC Announcement - Appointment
Capital/Financing Update Classification · 83% confidence The document is a Hong Kong Stock Exchange announcement required under Listing Rule 12.01C, informing the market of the appointment of overall coordinators (CLSA, Huatai, BOCOM) in connection with the Company’s intended public offering/listing. It does not present financial results, governance rules, or voting results, nor is it a prospectus; rather, it relates to the financing process of an IPO. This aligns with the Capital/Financing Update category (CAP).
2024-12-30 English
Application Proof (1st submission)
Audit Report / Information Classification · 95% confidence The document is an 'Application Proof' from the Hong Kong Stock Exchange (HKEX) for TransThera Sciences (Nanjing), Inc. - B. An 'Application Proof' is a preliminary version of a prospectus filed by a company intending to list on the stock exchange. In the context of the provided categories, this document represents the formal filing of materials for an Initial Public Offering (IPO) process. Since there is no specific 'IPO' or 'Prospectus' category, and it is a regulatory filing on the HKEX platform, it falls under 'Regulatory Filings' (RNS). FY 2024
2024-12-30 English
Application Proof (1st submission)
Regulatory Filings Classification · 95% confidence The document is titled as an "Application Proof" for TransThera Sciences (Nanjing), Inc., and it is explicitly stated multiple times that it is a draft, incomplete, and subject to change. It is described as a document required by the Stock Exchange of Hong Kong and the Securities and Futures Commission for providing information to the public in Hong Kong. The text emphasizes that this document is not a prospectus or an offer to sell securities and that no investment decision should be based on it. It also mentions that the final listing document (prospectus) will be registered later and that this document is not the final listing document. The document contains sections like expected timetable, summary, definitions, risk factors, and other preparatory information typical of a listing or IPO application proof. There is no actual financial data or financial statements presented, nor is this a report of financial results or management discussion. The document is a draft application proof related to a securities offering and listing process, which is a regulatory filing related to the IPO process but not the final prospectus or offering document. Given these characteristics, the document fits best into the category of Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories. It is not a report publication announcement because it is the application proof itself, not an announcement of a report publication. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2024-12-30 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.